anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to new uses of known chelating compounds for the treatment of bacterial in fungal infections, particularly by methicilllin-resistant and other drug-resistant strains of bacteria and fungi. One of more chelating compound is administered with or without additional antibiotic or antifungal drugs to achieve improved therapy. Preferred chelating compounds include clioquinol, 5,7-dichloro-8-hydroxy-quinaldine, phanquinone, 5,7-dichloro-8-hydroxyquinoline, 5,7- di-iodo-8-hydroxyquinoline. By chelation of specific metal ions, these compounds treat any infection by bacteria or fungi whose pathogenicity depends upon metalloenzymes that require these cations. The compounds are also effective against infections caused by extended β lactamase and metallo β lactamase producing bacterial strains. Bacteria targeted by these methods include methicillin-resistant  Staphylococcus aureus , penicillin resistant or intermediate resistant  Streptococcus pneumoniae  and other gram positive and multiresistant gram negative species and strains.
PURPOSE: A composition containing Patriniae Radix ethanol extract is provided to induce lung cancer cell apoptosis and to effectively prevent and treat lung cancer. CONSTITUTION: A composition for preventing and treating lung cancer contains Patriniae Radix ethanol extract as an active ingredient. The ethanol is 95% ethanol. The composition contains pharmaceutically acceptable carriers or diluents. The lung cancer is non-small cell lung cancer. A functional food for preventing lung cancer contains the ethanol extract containing sitologically acceptable food additives. [Reference numerals] (AA) Patriniae Radix
The intervention group will receive Child Abuse Prevention Problem Solving (CAPPS), a one-on-one, workbook-based intervention of six sessions, each lasting approximately 30-60 minutes. CAPPS is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. Sessions will be delivered at the medical home by bachelor level providers, whose availability and level of training mimic those of existing medical home care coordinators.
Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting). If severe hypoglycemia occurs, patients should be instructed to seek emergency treatment.

In patients with heart failure and diabetes, carvedilol therapy may lead to worsening hyperglycemia, which responds to intensification of hypoglycemic therapy. It is recommended that blood glucose be monitored when carvedilol dosing is initiated, adjusted, or discontinued. Trials designed to examine the effects of carvedilol on glycemic control in patients with diabetes and heart failure have not been conducted. 

In a trial designed to examine the effects of carvedilol on glycemic control in a population with mild-to-moderate hypertension and well-controlled type 2 diabetes mellitus, carvedilol had no adverse effect on glycemic control, based on HbA1c measurements [see Clinical Studies (14.4)].
The invention provides a nutritional preparation with selective whitening spot-removing efficacy and application thereof in medicinal cosmetics. The nutritional preparation is prepared by compounding of azelaic acid oligopeptide, ascorbic acid oligopeptide, tranexamic acid oligopeptide, retinoic acid oligopeptide, kojic acid oligopeptide, hydroxy acid oligopeptide, ellagic acid oligopeptide and other raw materials, and the oligopeptide is one or a compound of multiple of dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptides, nanopeptide and decapeptide. The medicinal cosmetics prepared form the nutritional preparation are original liquids, water preparations, masks, cream lotion, liquid foundation cream, gel, essence and other preparation forms. The cosmetics are prepared by compounding of the nutritional preparation, penetrating agents and auxiliary materials. The penetrating agents are plant essential oils, azone, carbitol and other medical penetrating agents. The auxiliary materials are thickeners, emulsifiers, packet agents, wetting agents, emollients, flavoring agents, preservatives and solvents which are used as main medicinal raw materials. A large number of clinical trials prove that the medicinal cosmetics prepared form the nutritional preparation have good selective whitening spot-removing and nutritional efficacy for the skin of human body.
Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
INTRODUCTION: This study aims to investigate the effectiveness of intravenous ibuprofen or intravenous ibuprofen plus acetaminophen compared to intravenous morphine in patients with closed extremity fractures.
METHODS: A triple-blinded randomized clinical trial was conducted at a tertiary trauma center in Iran. Adult patients between 15 and 60 years old with closed, isolated limb fractures and a pain intensity of at least 6/10 on the visual analog scale (VAS) were eligible. Patients with specific conditions or contraindications were not included. Participants were randomly assigned to receive intravenous ibuprofen, intravenous ibuprofen plus acetaminophen, or intravenous morphine. Pain scores were assessed using the visual analog scale at baseline and 5, 15, 30, and 60 min after drug administration. The primary outcome measure was the pain score reduction after one hour.
RESULTS: Out of 388 trauma patients screened, 158 were included in the analysis. There were no significant differences in age or sex distribution among the three groups. The pain scores decreased significantly in all groups after 5 min, with the morphine group showing the lowest pain score at 15 min. The maximum effect of ibuprofen was observed after 30 min, while the ibuprofen-acetaminophen combination maintained its effect after 60 min. One hour after injection, pain score reduction in the ibuprofen-acetaminophen group was significantly more than in the other two groups, and pain score reduction in the ibuprofen group was significantly more than in the morphine group.
CONCLUSION: The study findings suggest that ibuprofen and its combination with acetaminophen have similar or better analgesic effects compared to morphine in patients with closed extremity fractures. Although morphine initially provided the greatest pain relief, its effect diminished over time. In contrast, ibuprofen and the ibuprofen-acetaminophen combination maintained their analgesic effects for a longer duration. The combination therapy demonstrated the most sustained pain reduction. The study highlights the potential of non-opioid analgesics in fracture pain management and emphasizes the importance of initiation of these medications as first line analgesic for patients with fractures. These findings support the growing trend of exploring non-opioid analgesics in pain management.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05630222 (Tue, Nov 29, 2022). The manuscript adheres to CONSORT guidelines.
Endotoxins are pyrogenic lipopolysaccharides from Gram-negative bacteria that are known to induce fever, septic shock, and multiple organ failure, posing a substantial risk to human health. Drinking water systems are especially prone to home microbiomes containing a large variety of Gram-negative bacteria. Consumption of water from these systems in developed countries is generally regarded as non-hazardous to humans due to the low number of non-pathogenic bacterial cells per milliliter and oral admission. To assess potential risks posed by endotoxins in drinking water systems, we conducted a conventional microbiological investigation on a local community water system in the north of Germany and mined the resulting data to investigate the endotoxin contents of some of the most abundant microbiota found during these analyses. Using a Limulus amoebocyte lysate (LAL) -based endotoxin detection method, average normalized endotoxin content was determined. Although the average culturable amounts of microbiota in the drinking water system were insufficient to exert endotoxin levels critical to human health, peaks and acute contaminations may pose substantial health risks.
1,131,910. Radioactive isotopes. UNION CARBIDE CORP. 22 Aug., 1967 [17 Jan., 1967], No. 38525/67. Heading G6R. Technetium-99m (Tc-99m) is produced by extracting an aqueous solution containing Mo-99 and Tc-99m with an organic solvent, separating and drying the organic phase with a dehydrating agent, evaporating the organic solvent leaving Tc-99m as a residue, and taking up the residue in a liquid. An irradiated or fission product Mo compound, e.g. MoO 3 , is dissolved in an aqueous solution containing a salt, acid, or alkali, e.g. a concentrated solution of K 2 CO 3 ; hydrogen peroxide or bromine may be added to bring the Tc to its highest oxidation state. The Tc is preferentially extracted with methyl ethyl ketone, and the organic layer is washed with Na 2 CO 3  solution and dried with anhydrous K 2 CO 3 . The solvent is removed by evaporation and the residue dissolved in a pharmaceutically acceptable saline solution for use in medical research or diagnosis. The isotope may also be used in measurement of flow rates, process control, and radiometric chemistry. Other specified Mo compounds, salts, acids, and alkalies, organic solvents, and dehydrating agents may be used.
The invention relates to an application of lariciresinol-4-O-beta-D-glucoside in the preparation of drugs for treating or preventing flu and related inflammatory diseases caused by influenza virus. The application of lariciresinol-4-O-beta-D-glucoside in clinical treatment of influenza virus diseases has characteristics of safety, effectivity and little toxic or side effect. The invention also provides a pharmaceutical composition, an active ingredient of which comprises lariciresinol-4-O-beta-D-glucoside. By cytopathic-effect inhibition assay, it is verified that lariciresinol-4-O-beta-D-glucoside has an effect of inhibiting replication of influenza virus in the treatment mode. The result proves that lariciresinol-4-O-beta-D-glucoside has obvious effect of inhibiting influenza virus in the treatment mode. Selection index SI is greater than 4. The lariciresinol-4-O-beta-D-glucoside has advantages of low toxicity and high effectiveness.
Cancer patients undergoing treatment with antineoplastic drugs often experience chemotherapy-induced neuropathic pain (CINP), and the therapeutic options for managing CINP are limited. Here, we show that systemic paclitaxel administration upregulates the expression of neurotrophin-3 (Nt3) mRNA and NT3 protein in the neurons of dorsal root ganglia (DRG), but not in the spinal cord. Blocking NT3 upregulation attenuates paclitaxel-induced mechanical, heat, and cold nociceptive hypersensitivities and spontaneous pain without altering acute pain and locomotor activity in male and female mice. Conversely, mimicking this increase produces enhanced responses to mechanical, heat, and cold stimuli and spontaneous pain in naive male and female mice. Mechanistically, NT3 triggers tropomyosin receptor kinase C (TrkC) activation and participates in the paclitaxel-induced increases of C-C chemokine ligand 2 (Ccl2) mRNA and CCL2 protein in the DRG. Given that CCL2 is an endogenous initiator of CINP and that Nt3 mRNA co-expresses with TrkC and Ccl2 mRNAs in DRG neurons, NT3 likely contributes to CINP through TrkC-mediated activation of the Ccl2 gene in DRG neurons. NT3 may be thus a potential target for CINP treatment.
Over the past few decades, there has been a global surge in the prevalence of obesity, rendering it a globally recognized epidemic. Contrary to simply being a medical condition, obesity is an intricate disease with a multifactorial aetiology. Understanding the precise cause of obesity remains a challenge; nevertheless, there seems to be a complex interplay among biological, psychosocial and behavioural factors. Studies on the genetic factors of obesity have revealed several pathways in the brain that play a crucial role in food intake regulation. The best characterized pathway, thus far, is the leptin-melanocortin pathway, from which disruptions are responsible for the majority of monogenic obesity disorders. The effectiveness of conservative lifestyle interventions in addressing monogenic obesity has been limited. Therefore, it is crucial to complement the management strategy with pharmacological and surgical options. Emphasis has been placed on developing drugs aimed at replacing the absent signals, with the goal of restoring the pathway. In both monogenic and polygenic forms of obesity, outcomes differ across various interventions, likely due to the multifaceted nature of the disease. This underscores the need to explore alternative therapeutic strategies that can mitigate this heterogeneity. Precision medicine can be regarded as a powerful tool that can address this concern, as it values the understanding of the underlying abnormality triggering the disease and provides a tailored treatment accordingly. This would assist in optimizing outcomes of the current therapeutic approaches and even aid in the development of novel treatments capable of more effectively managing the global obesity epidemic.
This is a single-center, randomized, controlled, assessor-blinded clinical trial. Neonates born in UP-PGH or infants (\< 1 year of age) in the general pediatric wards for any condition who have diaper dermatitis are recruited and randomized to treatment with either Calmoseptine Ointment or Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste as part of a structured skin care regimen. Each participant has one week total participation, unless withdrawn. Baseline data are collected and study treatment initiated on study entry day. Treatment continued and follow up data collected on six subsequent follow up days. Primary outcome: healing of Diaper Dermatitis after six days of treatment, defined as a Diaper Dermatitis Severity Score of zero attributed by blinded assessment. Secondary outcomes: Diaper Dermatitis Severity Score at each day of treatment; size of affected area; incidence of Candida infection; adverse events.

Zinc Oxide Ointment preparations including Calmoseptine Ointment and Desitin Maximum Strength 40% Diaper Rash Paste have been used to treat diaper dermatitis for many years around the world. There are no known reported hypersensitivities to either product and no reported serious adverse events. As the proposed study is in neonates and infants, as a precaution the evidence relating to the safety and toxicity of individual ingredients were reviewed for the trial protocol prior to commencement.
FIELD: medicine. SUBSTANCE: preparation has granules containing mixture of enalapryl maleate, lactose, starch and polyvinylpyrralidone dusted with magnesium stearate and hydrocarbonate in given proportion. The method involves mixing enalapryl maleate, lactose, potato starch, moistening the mixture with polyvinylpyrralidone alcohol solution. The mixture is granulated under humid conditions with ethyl alcohol sprayed over the pseudoliquified mass. The granulated product is dried, dusted and tablets are produced. EFFECT: high quality of tablets dissociating during 1 min; provided high strength properties. 3 cl, 1 tbl
OBJECTIVES: The Node-RADS score was recently introduced to offer a standardized assessment of lymph node invasion (LNI). We tested its diagnostic performance in accurately predicting LNI in breast cancer (BC) patients with magnetic resonance imaging. The study also explores the consistency of the score across three readers.
MATERIALS AND METHODS: A retrospective study was conducted on BC patients who underwent preoperative breast contrast-enhanced magnetic resonance imaging and lymph node dissection between January 2020 and January 2023. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated for different Node-RADS cut-off values. Pathologic results were considered the gold standard. The overall diagnostic performance was evaluated using receiver operating characteristic curves and the area under the curve (AUC). A logistic regression analysis was performed. Cohen's Kappa analysis was used for inter-reader agreement.
RESULTS: The final population includes 192 patients and a total of 1134 lymph nodes analyzed (372 metastatic and 762 benign). Increasing the Node-RADS cut-off values, specificity and PPV rose from 71.4% to 100% and 76.7% to 100%, respectively, for Reader 1, 69.4% to 100% and 74.6% to 100% for Reader 2, and from 64.3% to 100% and 72% to 100% for Reader 3. Node-RADS > 2 could be considered the best cut-off value due to its balanced performance. Node-RADS exhibited a similar AUC for the three readers (0.97, 0.93, and 0.93). An excellent inter-reader agreement was found (Kappa values between 0.71 and 0.83).
CONCLUSIONS: The Node-RADS score demonstrated moderate-to-high overall accuracy in identifying LNI in patients with BC, suggesting that the scoring system can aid in the identification of suspicious lymph nodes and facilitate appropriate treatment decisions.
CLINICAL RELEVANCE STATEMENT: Node-RADS > 2 can be considered the best cut-off for discriminating malignant nodes, suggesting that the scoring system can effectively help identify suspicious lymph nodes by staging the disease and providing a global standardized language for clear communication.
KEY POINTS: Axillary lymphadenopathies in breast cancer are crucial for determining the disease stage. Node-RADS was introduced to provide a standardized evaluation of breast cancer lymph nodes. RADS > 2 can be considered the best cut-off for discriminating malignant nodes.
The invention discloses a composite preparation for improving the thickness of an endometrium, and belongs to the technical field of biological medicines. The compound preparation consists of the following components: 1-3 ml of endometrium stem cell suspension; 2-4 ml of acellular endometrium; PRP, 0.5-1.2 ml; TGF-beta neutralizing antibody with the final concentration of 0.5-3 ng/ml; CXCL5, the final concentration is 0.5-3 ng/ml. The composite preparation for improving the thickness of the endometrium contains the endometrium stem cells, and can repair the endometrium. Contains PRP and provides growth factor. Contains endometrium gel as support of endometrium stem cell. Contains TGF-beta 1 neutralizing antibody, and can avoid the formation of endometrial scar. Containing CXCL5, it has beneficial effects in controlling inflammatory processes. All components act together to achieve a therapeutic effect of improving endometrial thickness.
Patients who have had a normal screening mammogram within the last 6 months will be invited to participate. Accrual to Cohort D is complete.
This study reports a novel immunopotentiating effect of a lectin (FFrL) extracted from the mushroom  Fomitella fraxinea  on poultry cell-mediated immunity and poultry coccidiosis. We describe the extraction of FFrL, its in vitro mitogenic activity and in vivo protection against an oral challenge infection with  Eimeria acervulina . When tested on several cell types, crude FFrL agglutinated mouse erythrocytes and thymocytes and also various other cells including murine and human cell lines. However, crude FFrL did not agglutinate human A, B, AB, or O erythrocytes. FFrL showed a potent mitogenic activity on chicken splenic lymphocytes where at lower concentrations, crude FFrL exerted stronger mitogenic activity than Con A, a well-known potent mitogen for T lymphocytes. Further, FFrL significantly induced (P<0.05) nitric oxide secretion in HD11 cells, an established macrophage cell line, and suppressed (P<0.05) RP9 tumor cell growth, both, in a dose-dependent fashion. When injected into eighteen-day-old chicken embryos followed by an oral  E. acervulina  challenge infection, FFrL-treatment significantly protected chickens against weight loss associated with coccidiosis (P<0.05). Injecting embryos with FFrL also resulted in significant reduction in oocyst shedding as compared to the control saline-injected birds (P<0.05). The results of this study demonstrate that FFrL is an effective growth-promoting and immunostimulating agent in poultry during coccidiosis.
An oligonucleotide having whitening effect is provided to suppress the movement of melanosome from a melanocyte to keratocyte. A whitening agent comprises 15bp-25bp of antisense oligonucleotide which is complementary sequence to mRNA of kinesin gene. The antisense oligonucleotide is 15bp-25 bp of oligonucleotide having complementary sequence to mRNA of human kinesin heavy chain gene (GeneBank Accession No. X65873). The antisense oligonucleotide is selected from gene sequence of the sequence numbers 1(SEQ ID NO:1) to 8. The content of antisense oligonucleotide is 0.00001-10.0 weight%. The oligonucleotide is phosphorothioate oligonucleotide.
Gentamicin Sulfate Injection, USP is a sterile, nonpyrogenic solution of gentamicin sulfate in water for injection. It is administered by the intramuscular or intravenous route.

Each milliliter (mL) contains gentamicin sulfate equivalent to 40 mg gentamicin base with sodium metabisulfite 2.9 mg and edetate disodium anhydrous 0.1 mg added as stabilizer, methylparaben 1.8 mg and propylparaben 0.2 mg added as preservatives. Headspace nitrogen gassed. May contain sulfuric acid and/or sodium hydroxide for pH adjustment. The pH is 3.8 (3.0 to 5.5).

Gentamicin is classified as an aminoglycoside antibiotic and is derived from Micromonospora purpurea, an actinomycete.

The chemical name for gentamicin C1A is: 0-3-Deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)-0-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1→4)]-2-deoxy-D-streptamine.

Gentamicin Sulfate, USP is chemically designated gentamicin sulfate, a white to buff powder soluble in water. It has the following structural formula:
BACKGROUND: The combination of cross-facial nerve graft (CFNG) and masseteric nerve transfer (MNT) for reinnervation of facial paralysis may provide advantages of both neural sources. However, quantitative functional outcome reports with a larger number of patients are lacking in the literature. Here, the authors describe their 8-year experience with this surgical technique.
METHODS: Twenty patients who presented with complete facial paralysis (duration, <12 months) received dual reinnervation with CFNG and MNT. The functional outcome of the procedure was evaluated with the physician-graded outcome metric eFACE scale. The objective artificial intelligence-driven software Emotrics and FaceReader were used for oral commissure measurements and emotional expression assessment, respectively.
RESULTS: The mean follow-up was 31.75 ± 23.32 months. In the eFACE score, the nasolabial fold depth and oral commissure at rest improved significantly ( P < 0.05) toward a more balanced state after surgery. Postoperatively, there was a significant decrease in oral commissure asymmetry while smiling (from 19.22 ± 6.1 mm to 12.19 ± 7.52 mm). For emotional expression, the median intensity score of happiness, as measured by the FaceReader software, increased significantly while smiling (0.28; interquartile range, 0.13 to 0.64). In five patients (25%), a secondary static midface suspension with fascia lata strip had to be performed because of unsatisfactory resting symmetry. Older patients and patients with greater preoperative resting asymmetry were more likely to receive static midface suspension.
CONCLUSION: The authors' results suggest that the combination of MNT and CFNG for reinnervation of facial paralysis provides good voluntary motion and may lessen the use of static midface suspension in the majority of patients.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.